Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,430.00 | |
50 mg | 6-8 weeks | $ 1,860.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor. |
In vitro | D3 receptor antagonist SB269,652 effectively abolished specific binding of [(3)H]nemanopride and [(3)H]spiperone to Chinese hamster ovary-transfected D(3) receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations even at high concentrations (5 μM). By analogy, although SB269,652 potently blocked D(3) receptor-mediated activation of Gα(i3) and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gα(i3) [1]. |
Molecular Weight | 426.55 |
Formula | C27H30N4O |
CAS No. | 215802-15-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB269652 215802-15-6 Others SB-269652 SB 269652 inhibitor inhibit